NCT00107770View on ClinicalTrials.gov

Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

September 30, 2007

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

sodium phenylbutyrate

histone deacteylase inhibitor

Trial Locations (10)

13210

VA Medical Center, Syracuse, Syracuse

15240

VA Pittsburgh Health Care System, Pittsburgh

21201

VA Maryland Health Care System, Baltimore, Baltimore

27705

VA Medical Center, Durham, Durham

40502

VA Medical Center, Lexington, Lexington

45220

VA Medical Center, Cincinnati, Cincinnati

77030

Michael E. DeBakey VA Medical Center (152), Houston

52246-2208

VA Medical Center, Iowa City, Iowa City

01730

Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Bedford

02130

VA Medical Center, Jamaica Plain Campus, Boston

All Listed Sponsors
collaborator

Muscular Dystrophy Association

OTHER

lead

US Department of Veterans Affairs

FED

NCT00107770 - Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis) | Biotech Hunter | Biotech Hunter